Company Filing History:
Years Active: 2007-2009
Title: Jamie Rossjohn: Innovator in Cytokine Research
Introduction
Jamie Rossjohn is a prominent inventor based in Carnegie, Australia. She has made significant contributions to the field of cytokine research, particularly through her innovative patents. With a total of 2 patents, her work focuses on understanding and manipulating cytokine signaling pathways, which are crucial for various biological processes.
Latest Patents
One of Jamie's latest patents is titled "Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof." This invention relates to X-ray crystallography studies of the JAK2 domain, specifically the crystal structure of a JAK2 kinase domain bound to an inhibitor. The invention aims to utilize the crystal and related structural information to select and screen for compounds that interact with JAK2 and related proteins, potentially leading to treatments for diseases mediated by inappropriate JAK2 activity.
Another significant patent is "Cytokine binding domain of cytokine receptors." This invention provides a cytokine-binding domain that binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor. The patent also outlines methods for identifying compounds with cytokine agonist or antagonist activity, focusing on GM-CSF, IL-3, and IL-5.
Career Highlights
Throughout her career, Jamie has worked with notable companies such as Cytopia Research Pty Ltd and Medvet Science Pty Ltd. Her expertise in cytokine research has positioned her as a key figure in the development of therapeutic strategies targeting cytokine signaling.
Collaborations
Jamie has collaborated with esteemed colleagues, including Andrew Frederick Wilks and Christopher John Burns. These partnerships have further enhanced her research and contributed to advancements in the field.
Conclusion
Jamie Rossjohn's innovative work in cytokine research and her valuable patents highlight her significant contributions to the scientific community. Her ongoing efforts continue to pave the way for new therapeutic approaches in treating diseases related to cytokine signaling.